World Hepatitis Alliance

26/10/2026

Are you working to improve the health and wellbeing of people who use drugs in Southeast Asia?

Abstracts are now open for WHA partner, INHSU’s, Southeast Asia Regional Conference 2027, taking place at Universiti Malaya in Kuala Lumpur from 15–17 June 2027. Abstracts are invited on HIV, viral hepatitis, harm reduction, drug policy, community-led responses and other issues affecting people who use drugs.

Submissions are open to people based in Southeast Asia and those whose work focuses on the region.

Abstracts close 30 November 2026. The conference is free to attend, with 200 places available. Find out more, submit an abstract, or express interest in attending:

If you’re working to improve the health or rights of people who use drugs, INHSU 2026 is a must-attend event. A vibrant space where research, practice, policy, and lived experience come together on equal footing.

22/10/2026

How can we strengthen hepatitis A prevention and reduce deaths worldwide?

The World Hepatitis Alliance (WHA) will bring together a wide range of speakers for a webinar exploring how countries are responding to hepatitis A and what more can be done to turn advocacy into action. The event builds on WHA’s 2025 advocacy briefing and discussions at the 2026 World Hepatitis Summit.

Taking place on Thursday 29 October, from 1pm to 2pm GMT, the webinar will feature presentations and an audience Q&A, chaired by Dee Lee, President of the World Hepatitis Alliance. Speakers include:
- Dr Ajeet Bhadoria, Additional Professor, All India Institute of Medical Sciences Rishikesh, India
- Marea Gordon, University of California San Diego School of Medicine, USA
- Dr Jaime Jesús Pérez Martín, Specialist in Preventive Medicine and Public Health, Deputy Director General of Public Health of the Region of Murcia and President of the Spanish Association of Vaccinology

Further speakers will be announced.

Register now to join the discussion, hear international perspectives and help advance collective efforts to reduce hepatitis A deaths: https://us02web.zoom.us/webinar/register/WN_HQ_dW906RUuecHfBCoOaIw #/registration

Supported by MSD

The global hepatitis A landscape continues to evolve. Last year, the World Hepatitis Alliance (WHA) launched an advocacy briefing to increase awareness around hepatitis A, which included calls to action to help drive meaningful change. Building on this and discussions at the World Hepatitis Summit 2...

21/10/2026

A significant step has been taken today in the elimination of hepatitis B!

The U.S. Food and Drug Administration (FDA) has become the second country after Japan to approve bepirovirsen, a first-in-class treatment offering a functional cure for some adults living with chronic hepatitis B.

This is an important milestone for people living with hepatitis B, and the wider hepatitis community, but we now need to make sure that this innovation reaches the people who need it, across different countries and communities.

This will require us to address barriers to testing, diagnosis and treatment; including stigma and discrimination, so that people can access care without fear or delay.

We believe everyone living with hepatitis B should have access to timely diagnosis, effective care and the benefits of scientific progress. As new treatment options emerge, innovation must go hand in hand with equitable access in order to accelerate progress towards hepatitis elimination. Read more about the approval here:

FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.

20/10/2026

Hepatitis A remains an evolving global health challenge, requiring sustained advocacy and collaboration to prevent avoidable deaths.

Building on its 2025 advocacy briefing, the World Hepatitis Alliance is hosting a webinar on Thursday 29 October 2026 to explore how countries are responding to hepatitis A, the challenges they face, and how we can work together to advance action and save lives.

Register now to join the discussion: https://us02web.zoom.us/webinar/register/WN_HQ_dW906RUuecHfBCoOaIw #/registration

Supported by MSD

The global hepatitis A landscape continues to evolve. Last year, the World Hepatitis Alliance (WHA) launched an advocacy briefing to increase awareness around hepatitis A, which included calls to action to help drive meaningful change. Building on this and discussions at the World Hepatitis Summit 2...

19/10/2026

How can we turn advocacy into action to accelerate hepatitis elimination?

The World Hepatitis Alliance’s fifth Community Impact Accelerator Programme brought together 17 advocates from 13 countries across Africa, Asia, Europe, North America and Oceania to strengthen the skills and connections needed to drive change.

Through an in-person workshop at the 2026 World Hepatitis Summit in Bangkok and interactive virtual sessions, Group Five developed their knowledge and confidence in strategic advocacy, stakeholder engagement and turning ideas into practical action plans.

The impact speaks for itself: 85% of participants said they would definitely recommend the programme. Group Five leaves better equipped and connected to advance community-led advocacy and help achieve global hepatitis elimination by 2030. Read the report to discover more about Group Five’s experience:

16/10/2026

How can we make hepatitis B care more accessible and community-centred? Tackling stigma and discrimination is an essential part of the answer.

The World Hepatitis Alliance recently presented findings from its 2024 pilot stigma survey at the hepatitis B (HBV) Care Meeting, during a presentation titled “The Role of Stigma and Discrimination Related to Hepatitis B: Results from a Pilot Survey.” The survey, conducted in partnership with the European Centre for Disease Prevention and Control (ECDC), highlights how stigma can affect people’s relationships, wellbeing and access to healthcare.

Understanding and addressing these barriers is vital to building trusted, inclusive, community-centred services and ensuring that everyone affected by hepatitis B can access the care and support they need. Explore the survey findings and WHA’s resources on hepatitis-related stigma and discrimination here:

Fighting for a world free from viral hepatitis

15/10/2026

Liver cancer is the third most common cause of cancer deaths worldwide, with most cases linked to hepatitis. Although effective tools exist to prevent and treat viral hepatitis, these interventions are still not reaching everyone who needs them.

Awareness remains a significant challenge. Research conducted by the World Hepatitis Alliance (WHA) found that nearly half of people globally are unaware of the link between hepatitis and liver cancer, highlighting the need for greater public awareness and stronger action to prevent avoidable deaths.

During Liver Cancer Awareness Month, WHA is calling for greater investment and action to scale up hepatitis elimination efforts and reduce the burden of liver cancer. Through its white paper, Beating Cancer Through Hepatitis Elimination – Working Together to Reduce NCDs, WHA sets out key calls to action for policymakers that could make a transformative difference for people at risk.

Read the white paper to explore the recommendations and discover how accelerating hepatitis elimination can help prevent liver cancer: https://www.worldhepatitisalliance.org/whitepaper/

14/10/2026

“Success looks like no one dying from a preventable disease. No one should be dying from hepatitis B. There are vaccines, there’s effective treatment, and if we can get those to the people that need them in a timely fashion and bring in greater choice, more innovations, then no one should be dying from a preventable disease.” – Jessica Hicks, Senior Director, World Hepatitis Alliance

Jessica recently sat down with Dr. Kat Arney, and Joyeta Das from GSK on the "Behind the Science" podcast for a discussion on hepatitis B. Tune in to hear their thoughts on the current state of play, and what needs to be done to build awareness and get to those most affected:

Experts Joyeta Das & Jessica Hicks discuss a disease that is so qui...

13/10/2026

Thank you to everyone who joined our webinar introducing World Hepatitis Testing Week (WHTW) 2026! It was great to connect with advocates and partners committed to expanding access to hepatitis testing and accelerating progress towards elimination by 2030.

Missed the webinar, or want to revisit the discussion? Watch the recording here: https://www.youtube.com/watch?v=_b9ZI6NJe2s

Help spread the word! WHTW 2026 starts on 16 November, and we’re calling on everyone to help raise awareness and encourage more people to get tested. Explore and download our campaign resources, and help bring testing within reach for more communities: https://heptestweek.org/spread-the-word/

Use the official World Hepatitis Testing Week campaign resources to raise awareness online and in your community. Materials are available to download in a range of languages, or you can use the customisable poster and social media graphic tools to create your own materials in your language. Campaign...

12/10/2026

Nearly 300 million people are living with viral hepatitis worldwide, yet only around one third have been diagnosed. Despite having the tools to diagnose and treat hepatitis, access to testing remains out of reach for many. Urgent action is needed to close this gap and put elimination within reach by 2030.

Join the World Hepatitis Alliance tomorrow, Tuesday 13 October, at 12pm GMT for a 30-minute webinar introducing World Hepatitis Testing Week (WHTW) 2026, which starts on 16 November. Chaired by WHA President Dee Lee, with speakers Jessica Hicks, Senior Director, and Alexandra Smith, Advocacy and Engagement Manager, the webinar will explore the campaign and its new resources.

Register now: https://us02web.zoom.us/webinar/register/WN_pIGdN15UTHSnOGaMKWeMng #/registration
Simultaneous interpretation will be available in French and Spanish, and campaign resources will be available in Arabic, Chinese, English, French and Spanish. Together, we can expand access to testing, save lives and accelerate hepatitis elimination.

This link will take you to a page that’s not on LinkedIn